I meant ADAPT, from 2018 quarterly and still haven't received TGA approval.
"Emerging Markets performed well but growth was hindered by delayed Therapeutic Goods Administration (TGA) approval to launch ADAPT® in Australia which was anticipated during this quarter. This delay directly impacts revenue for Australia but also inhibits entry into other emerging markets such as Thailand, Taiwan, Vietnam and the Philippines, who favour applications with home market approval. Admedus has complied with all aspects of the stringent TGA process and remains confident of securing approval in the second half of this year."
I meant ADAPT, from 2018 quarterly and still haven't received...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |